AMGEN INC

Amgen reported strong financial results for the second quarter and first half of 2026. Total revenues for Q2 increased to $10.05 billion, with net income rising to $2.38 billion and diluted EPS reaching $4.37. The company also saw a significant increase in net cash provided by operating activities for the first six months of 2026. Amgen continues to contest substantial IRS tax claims totaling approximately $8.7 billion for prior periods, with a court decision expected in late 2026 or early 2027.

Amgen reported strong second-quarter 2026 financial results, with total revenues increasing 10% to $10.1 billion and GAAP EPS rising 65% to $4.37. The company's six key growth drivers contributed significantly, growing 26% year-over-year. While several products like Repatha and UPLIZNA showed substantial sales growth, others such as Prolia and XGEVA experienced declines due to biosimilar competition and the Inflation Reduction Act. Amgen also provided extensive updates on its pipeline, including multiple Phase 3 studies for MariTide and regulatory discussions for TAVNEOS and BLINCYTO.

Amgen Inc. identified unauthorized activity in its third-party cloud environments in July 2026, leading to the exfiltration of proprietary data and patient protected health information. The company activated its cybersecurity response plan and engaged forensic experts. While the investigation is ongoing, Amgen has not identified any impact on its products, manufacturing operations, or financial reporting systems. The incident was deemed material on July 29, 2026, though the company currently believes it is not reasonably likely to have a material impact on its financial condition or results of operations.

Amgen Inc. announced that Peter H. Griffith will retire from his role as Executive Vice President and Chief Financial Officer, effective August 31, 2026. He will continue in a non-executive capacity until January 31, 2027, and will receive retirement benefits. Concurrently, Thomas Dittrich has been appointed as the new Executive Vice President and Chief Financial Officer, effective September 1, 2026, after serving as an Executive Vice President from July 1, 2026. Mr. Dittrich's compensation package includes an annual base salary of CHF 1,070,000, significant equity awards, and one-time bonuses totaling CHF 14.55 million to compensate for foregone compensation and relocation.

Amgen reported strong first-quarter 2026 financial results, with total revenues increasing 6% to $8.6 billion and GAAP EPS rising 4% to $3.34. The company generated $1.5 billion in free cash flow and increased its quarterly dividend by 6% to $2.52 per share. Sixteen brands achieved double-digit sales growth, including Repatha (+34%) and UPLIZNA (+188%). However, the FDA issued a proposal to withdraw approval for TAVNEOS, citing a lack of substantial evidence of effectiveness, though Amgen intends to contest this. The company also discontinued development of AMG 193 and announced positive Phase 3 results for subcutaneous TEPEZZA.

Amgen Inc. announced the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026. His responsibilities will be redistributed among James E. Bradner (EVP, Research and Development, AI and Data), Murdo Gordon (EVP, Amgen Global Markets and Policy), and Peter H. Griffith (EVP and CFO), effective June 1, 2026. This move aims to further integrate science, technology, and data, and align commercial, medical, and policy teams.

Amgen announced its Q3 2025 financial results, reporting a 12% increase in total revenue to $9.6 billion compared to Q3 2024. GAAP earnings per share increased by 14% to $5.93, driven by higher revenues, partially offset by higher operating expenses, including an Otezla intangible asset impairment charge of $400 million.

Amgen has entered into a Termination Agreement with Kyowa Kirin to end their License and Collaboration Agreement, effective upon regulatory approval. The original agreement was dated June 1, 2021, and the termination could impact Amgen's future revenue streams and research collaborations.

Amgen announced its fourth quarter and full year 2025 financial results, reporting a 10% increase in full-year revenue to $36.8 billion and an 88% increase in GAAP earnings per share to $14.23. The company highlighted strong performance across its product portfolio, with several products achieving record sales, but also noted a $1.2 billion impairment charge related to Otezla due to Medicare price setting under the Inflation Reduction Act.

Amgen issued $4 billion in aggregate principal amount of senior notes across four tranches with maturities ranging from 2031 to 2056. The proceeds, net of discounts and expenses, totaled approximately $3.96 billion and will likely be used for general corporate purposes, including potential acquisitions, debt repayment, or share repurchases, impacting Amgen's capital structure and financial flexibility.